Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Apr 27;7(24):36510–36528. doi: 10.18632/oncotarget.9058

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2016 Bai et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

A. Effect of rosiglitazone on the expression of E-cadherin, Vimentin and Collagen IV compared between conditions. B. Increased PPARγ (green) and E-cadherin (red) with rosiglitazone treatment and overlaid image showing colocalization (yellow, arrows) in high glucose condition (30 mM). C. Rosiglitazone upregulated E-cadherin but downregulated Vimentin and Collagen IV. D. Decreased migrated cells with rosiglitazone treatment. E. Decreased invaded distance with rosiglitazone treatment. Results are presented as mean ± SD of three independent experiments. *P<0.05, #P<0.001 compared with DMSO. EMT, epithelial-to-mesenchymal transition; Rosi.: rosiglitazone. , DMSO; , Rosi.

Inline graphic — A. Effect of rosiglitazone on the expression of E-cadherin, Vimentin and Collagen IV compared between conditions. B. Increased PPARγ (green) and E-cadherin (red) with rosiglitazone treatment and overlaid image showing colocalization (yellow, arrows) in high glucose condition (30 mM). C. Rosiglitazone upregulated E-cadherin but downregulated Vimentin and Collagen IV. D. Decreased migrated cells with rosiglitazone treatment. E. Decreased invaded distance with rosiglitazone treatment. Results are presented as mean ± SD of three independent experiments. *P<0.05, #P<0.001 compared with DMSO. EMT, epithelial-to-mesenchymal transition; Rosi.: rosiglitazone. , DMSO; , Rosi.